These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 36248222)

  • 1. Severe Hypophosphatemia Occurring After Repeated Exposure to a Parenteral Iron Formulation.
    Haridas K; Yau A
    Case Rep Endocrinol; 2022; 2022():1011401. PubMed ID: 36248222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Symptomatic severe hypophosphatemia after intravenous ferric carboxymaltose.
    Fang W; McMahon LP; Bloom S; Garg M
    JGH Open; 2019 Oct; 3(5):438-440. PubMed ID: 31633052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial of intravenous iron-induced hypophosphatemia.
    Wolf M; Chertow GM; Macdougall IC; Kaper R; Krop J; Strauss W
    JCI Insight; 2018 Dec; 3(23):. PubMed ID: 30518682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk Factors for and Effects of Persistent and Severe Hypophosphatemia Following Ferric Carboxymaltose.
    Schaefer B; Zoller H; Wolf M
    J Clin Endocrinol Metab; 2022 Mar; 107(4):1009-1019. PubMed ID: 34850000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women.
    Wolf M; Koch TA; Bregman DB
    J Bone Miner Res; 2013 Aug; 28(8):1793-803. PubMed ID: 23505057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of ferric carboxymaltose on markers of mineral and bone metabolism: A single-center prospective observational study of women with iron deficiency.
    Frazier R; Hodakowski A; Cai X; Lee J; Zakarija A; Stein B; David V; Wolf M; Isakova T; Mehta R
    Bone; 2020 Dec; 141():115559. PubMed ID: 32730929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hypophosphatemia following the administration of intravenous iron formulations: A case report and literature review].
    Lecoq AL; Dong C; Carbonnel F; Becquemont L
    Therapie; 2021; 76(6):705-714. PubMed ID: 33962799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral Iron Replacement Normalizes Fibroblast Growth Factor 23 in Iron-Deficient Patients With Autosomal Dominant Hypophosphatemic Rickets.
    Imel EA; Liu Z; Coffman M; Acton D; Mehta R; Econs MJ
    J Bone Miner Res; 2020 Feb; 35(2):231-238. PubMed ID: 31652009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypophosphatemia after intravenous iron therapy: Comprehensive review of clinical findings and recommendations for management.
    Schaefer B; Tobiasch M; Wagner S; Glodny B; Tilg H; Wolf M; Zoller H
    Bone; 2022 Jan; 154():116202. PubMed ID: 34534708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study.
    Schouten BJ; Hunt PJ; Livesey JH; Frampton CM; Soule SG
    J Clin Endocrinol Metab; 2009 Jul; 94(7):2332-7. PubMed ID: 19366850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of fibroblast growth factor 23 (FGF23) in the metabolism of phosphorus and calcium immediately after kidney transplantation.
    Sánchez Fructuoso AI; Maestro ML; Calvo N; De La Orden V; Pérez Flores I; Vidaurreta M; Valero R; Fernández-Pérez C; Barrientos A
    Transplant Proc; 2012 Nov; 44(9):2551-4. PubMed ID: 23146451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials.
    Wolf M; Rubin J; Achebe M; Econs MJ; Peacock M; Imel EA; Thomsen LL; Carpenter TO; Weber T; Brandenburg V; Zoller H
    JAMA; 2020 Feb; 323(5):432-443. PubMed ID: 32016310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe Symptomatic Hypophosphataemia as a Complication of Parenteral Iron Replacement.
    Teh KK; Chuah MB; Tay SW; Lim AY; Khoo JJ
    Eur J Case Rep Intern Med; 2020; 7(11):001860. PubMed ID: 33194864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous iron administration and hypophosphatemia in clinical practice.
    Hardy S; Vandemergel X
    Int J Rheumatol; 2015; 2015():468675. PubMed ID: 26000018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Osteomalacia following intravenous iron suppletion].
    Koks N; Donga E; Appelman-Dijkstra NM
    Ned Tijdschr Geneeskd; 2021 Oct; 165():. PubMed ID: 34854600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron-induced hypophosphatemia: an emerging complication.
    Zoller H; Schaefer B; Glodny B
    Curr Opin Nephrol Hypertens; 2017 Jul; 26(4):266-275. PubMed ID: 28399017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A rare case of parental iron-induced persistent hypophosphatemia.
    Sullivan A; Lanham T; Rubin A
    J Community Hosp Intern Med Perspect; 2020 May; 10(2):166-167. PubMed ID: 32850057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypophosphatemia after high-dose iron repletion with ferric carboxymaltose and ferric derisomaltose-the randomized controlled HOMe aFers study.
    Emrich IE; Lizzi F; Siegel JD; Seiler-Mussler S; Ukena C; Kaddu-Mulindwa D; D'Amelio R; Wagenpfeil S; Brandenburg VM; Böhm M; Fliser D; Heine GH
    BMC Med; 2020 Jul; 18(1):178. PubMed ID: 32654663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous Iron-Induced Hypophosphatemia: An Emerging Syndrome.
    Glaspy JA; Wolf M; Strauss WE
    Adv Ther; 2021 Jul; 38(7):3531-3549. PubMed ID: 34053011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.